MedTrace Logo

Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma

NCT00003667 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-25

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy with or without biological therapy in treating patients who have newly diagnosed high-risk Ewing's sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

cyclophosphamide

DRUG

dexrazoxane hydrochloride

DRUG

disaccharide tripeptide glycerol dipalmitoyl

DRUG

doxorubicin hydrochloride

DRUG

vincristine sulfate

PROCEDURE

surgical procedure

RADIATION

radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Paul A. Meyers, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
3 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Primary Completion
2000-08-31
Completion
2000-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003667 on ClinicalTrials.gov